Frank van Leth
Frank van Leth
VU Amsterdam, Department of Health Sciences
Verified email at vu.nl - Homepage
Title
Cited by
Cited by
Year
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the …
F Van Leth, P Phanuphak, K Ruxrungtham, E Baraldi, S Miller, B Gazzard, ...
The Lancet 363 (9417), 1253-1263, 2004
8452004
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?
E Fontas, F Van Leth, CA Sabin, N Friis-Møller, M Rickenbach, ...
Journal of Infectious Diseases 189 (6), 1056-1074, 2004
3942004
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
C Lange, I Abubakar, JWC Alffenaar, G Bothamley, JA Caminero, ...
European Respiratory Journal 44 (1), 23-63, 2014
3222014
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
F Van Leth, P Phanuphak, E Stroes, B Gazzard, P Cahn, F Raffi, R Wood, ...
PLoS medicine 1 (1), e19, 2004
3132004
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile
M van der Valk, JJP Kastelein, RL Murphy, F van Leth, C Katlama, ...
Aids 15 (18), 2407-2414, 2001
3112001
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
R Van Leeuwen, C Katlama, RL Murphy, K Squires, J Gatell, A Horban, ...
Aids 17 (7), 987-999, 2003
2602003
Measuring tuberculosis burden, trends, and the impact of control programmes
C Dye, A Bassili, AL Bierrenbach, JF Broekmans, VK Chadha, P Glaziou, ...
The Lancet infectious diseases 8 (4), 233-243, 2008
2522008
Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study
M Sester, F van Leth, J Bruchfeld, D Bumbacea, DM Cirillo, AG Dilektasli, ...
American journal of respiratory and critical care medicine 190 (10), 1168-1176, 2014
2052014
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
F Van Leth, S Andrews, B Grinsztejn, E Wilkins, MK Lazanas, JMA Lange, ...
Aids 19 (5), 463-471, 2005
1972005
Are adverse events of nevirapine and efavirenz related to plasma concentrations
BS Kappelhoff, F van Leth, PA Robinson, TR MacGregor, E Baraldi, ...
Antivir Ther 10 (4), 489-98, 2005
1972005
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study
BS Kappelhoff, F van Leth, TR MacGregor, J Lange, JH Beijnen, ...
Antivir Ther 10 (1), 145-55, 2005
1452005
Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule
F van Leth, MJ Van der Werf, MW Borgdorff
Bulletin of the World Health Organization 86, 20-26, 2008
1352008
Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a systematic review
SJ Leopold, F van Leth, H Tarekegn, C Schultsz
Journal of Antimicrobial Chemotherapy 69 (9), 2337-2353, 2014
1242014
Multidrug-Resistant Tuberculosis in Europe, 2010–2011
G Günther, F van Leth, S Alexandru, N Altet, K Avsar, D Bang, R Barbuta, ...
Emerging infectious diseases 21 (3), 409, 2015
962015
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy
FV Leth, BS Kappelhoff, D Johnson, MH Losso, A Boron-Kaczmarska, ...
AIDS Research & Human Retroviruses 22 (3), 232-239, 2006
902006
National anti-tuberculosis drug resistance study in Tanzania
TM Chonde, D Basra, SGM Mfinanga, N Range, F Lwilla, RP Shirima, ...
The International Journal of Tuberculosis and Lung Disease 14 (8), 967-972, 2010
832010
Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy
W Worodria, M Massinga-Loembe, D Mazakpwe, K Luzinda, J Menten, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 58 (1), 32-37, 2011
702011
Treatment Outcomes in Multidrug-Resistant Tuberculosis
G Günther, C Lange, S Alexandru, N Altet, K Avsar, D Bang, R Barbuta, ...
New England Journal of Medicine 375 (11), 1103-1105, 2016
672016
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe
C Lange, R Duarte, M Fréchet-Jachym, G Guenther, L Guglielmetti, ...
American journal of respiratory and critical care medicine 194 (8), 1029-1031, 2016
622016
Adherence to tuberculosis therapy among patients receiving home-based directly observed treatment: evidence from the United Republic of Tanzania
A Mkopi, N Range, F Lwilla, S Egwaga, A Schulze, E Geubbels, ...
PloS one 7 (12), e51828, 2012
612012
The system can't perform the operation now. Try again later.
Articles 1–20